ZERO CANDIDA TECHNOLOGIES IN (ZCT.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:ZCT - CA9894831028 - Common Stock
ZCT.CA Key Statistics, Chart & Performance
The current stock price of ZCT.CA is 0.2 CAD. In the past month the price decreased by -20%.
ZCT.CA Latest News, Press Relases and Analysis
About ZCT.CA
Company Profile
Zero Candida Technologies, Inc. engages in the development and commercial exploitation of patents and patent applications with respect to an artificial intelligence smart tampon-like device. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2024-11-25. The firm is focused on commercial exploitation of a number of patents and patent applications with respect to an artificial intelligence (AI) smart tampon-like device, designed to treat Candidiasis and transfer the medical information through Wi-Fi to the doctor. Its technology is a combination of a therapy light source with a selected wavelength and intensity and a transparent gel-based drug delivery system to maintain the optimum Ph level in the vagina. The device, when used overnight, demonstrated 99.9999% Candidiasis elimination in the vagina within 3 nights. The device is based on smart technology that distributes light and a sensor that gathers and conveys data. The technology and the sensor itself are both patented, and together they provide focused and precise treatment, supported by scientific data. The ZC Device is designed to be re-used, such that the user only needs to clean or replace the coating before each use.
Company Info
ZERO CANDIDA TECHNOLOGIES IN
500- 666 Burrard Street
Vancouver BRITISH COLUMBIA CA
Employees: 0
Phone: 16478743767
ZERO CANDIDA TECHNOLOGIES IN / ZCT.CA FAQ
What does ZERO CANDIDA TECHNOLOGIES IN do?
Zero Candida Technologies, Inc. engages in the development and commercial exploitation of patents and patent applications with respect to an artificial intelligence smart tampon-like device. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2024-11-25. The firm is focused on commercial exploitation of a number of patents and patent applications with respect to an artificial intelligence (AI) smart tampon-like device, designed to treat Candidiasis and transfer the medical information through Wi-Fi to the doctor. Its technology is a combination of a therapy light source with a selected wavelength and intensity and a transparent gel-based drug delivery system to maintain the optimum Ph level in the vagina. The device, when used overnight, demonstrated 99.9999% Candidiasis elimination in the vagina within 3 nights. The device is based on smart technology that distributes light and a sensor that gathers and conveys data. The technology and the sensor itself are both patented, and together they provide focused and precise treatment, supported by scientific data. The ZC Device is designed to be re-used, such that the user only needs to clean or replace the coating before each use.
What is the stock price of ZERO CANDIDA TECHNOLOGIES IN today?
The current stock price of ZCT.CA is 0.2 CAD. The price decreased by -11.11% in the last trading session.
Does ZERO CANDIDA TECHNOLOGIES IN pay dividends?
ZCT.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ZCT stock?
ZCT.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the number of employees for ZERO CANDIDA TECHNOLOGIES IN?
ZERO CANDIDA TECHNOLOGIES IN (ZCT.CA) currently has 0 employees.
ZCT.CA Technical Analysis
ZCT.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ZCT.CA. ZCT.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
ZCT.CA Financial Highlights
Over the last trailing twelve months ZCT.CA reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS increased by 50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -248.82% | ||
| ROE | -449.37% | ||
| Debt/Equity | 0.01 |